Investigating microRNA for diagnosing and treating pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the role of microRNA (miRNA) in pancreatic cancer by collecting serum samples from patients with newly diagnosed pancreatic cancer. Researchers will analyze the miRNA profiles at various time points, including before treatment and monthly during treatment, to identify specific miRNAs that may serve as biomarkers for early diagnosis and treatment response. The study seeks to differentiate pancreatic cancer patients from healthy individuals and correlate miRNA levels with treatment outcomes, potentially leading to the development of a diagnostic test.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have biopsy proven adenocarcinoma of the pancreas
* Have initially inoperable disease, classified as either locally advanced or metastatic disease

  * Recurrent disease after a Whipple procedure is allowed
  * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
* Have radiographically measurable disease
* Have an ECOG performance status of 2 or less
* Be willing to contribute the required information and specimens
* Provide written signed consent to participate

Exclusion Criteria:

* Having received prior anti-cancer treatments for metastatic pancreatic cancer
* Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
* Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable

Where it's running

• Nuvance Health
  Norwalk, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Richard Frank, MD — Nuvance Health
• Study coordinator: Pramila Krumholtz, RN
• Email: pramila.krumholtz@nuvancehealth.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

• Microwave Ablation Feasibility for pancreatic and liver cancers guided by endoscopic ultrasound

  This study tests whether an ultrasound-guided microwave ablation device can be safely and effectively used in adults with locally advanced, unresectable, or metastatic pancreatic or liver cancers.

  Recruiting Banner Health · Gilbert, Arizona and 5 other locations · NCT07817147

• Combining Nab-Paclitaxel and Gemcitabine with SBP-101 for Pancreatic Cancer

  This study is testing if adding a new treatment called SBP-101 to the standard drugs nab-paclitaxel and gemcitabine can help people with untreated metastatic pancreatic cancer live longer and feel better.

  Recruiting at 77 sites Phase 2/3 Panbela Therapeutics, Inc. · Hot Springs, Arkansas and 92 other locations · NCT05254171

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

• T cell therapy targeting KRAS G12V mutation for advanced pancreatic cancer

  This study is testing a new T cell therapy that uses patients' own immune cells to target a specific mutation in advanced pancreatic cancer to see if it can help them fight the disease.

  Recruiting Phase 1/2 Changhai Hospital · Shanghai · NCT04146298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.